VRCA
$6.31
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Recent News
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Verrica Pharmaceuticals Inc (VRCA) reports a 368% increase in annual revenue and extends its cash runway into 2027, despite challenges in sales force and competition.
Verrica Pharmaceuticals Q4 Earnings Call Highlights
Verrica Pharmaceuticals (NASDAQ:VRCA) used its fourth quarter and year-end 2025 corporate update call to highlight what management described as a “fundamental” business transformation driven by sharper commercial execution, pipeline progress, and a strengthened balance sheet. YCANTH commercial trac
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for February 2nd
LUV, VRCA, CVLT, FINW and SDVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2026.
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.